Cresemba (Isavuconazonium Sulfate) Patent Expiration, LOE Window & CMS Spending
Cresemba (Isavuconazonium Sulfate) by Astellas Pharma: FDA Orange Book core substance LOE 2026-04-30 (last listed 2031-06-08), 0 AB generics, $157.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Astellas Pharma |
| FDA Application & Pathway | N207500 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-04-30 |
| Last Listed Patent or Exclusivity Date | 2031-06-08 |
| Orange Book Patents (*PED Extensions) | 6 patents (3 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $157.2M |
| 2024 Medicare Part D Spend | $123.0M |
| 2024 Medicaid Spend | $34.2M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 17.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.